Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR)

NCT ID: NCT04046224

Last Updated: 2025-05-15

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 33 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-07-23
• Study Completion Date: 2025-04-10

Brief Summary

This is the first in human treatment with ST-920, a recombinant AAV2/6 vector encoding the cDNA for human a-Gal A. The purpose of this study is to evaluate the safety and tolerability of ascending doses of ST-920. ST-920 aims to provide stable, long-term production of α-Gal A at therapeutic levels in subjects with Fabry disease. The constant production of α-Gal A in humans should, importantly, enable reduction and potentially clearance of Fabry disease substrates Gb3 and lyso-Gb3. On Day 1, patients will be infused intravenously with a single dose of ST-920 and followed for a period of 52 weeks.

Conditions

Fabry Disease

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Sequential dose escalation

ST-920 is administered as a single infusion:

1. Cohort 1: 0.5e13 vg/kg

2. Cohort 2: 1.0e13 vg/kg

3. Cohort 3: 3.0e13 vg/kg

4. Cohort 4: 5.0e13 vg/kg

Group Type: EXPERIMENTAL

ST-920

Intervention Type: BIOLOGICAL

Single dose of investigational product ST-920

Expansion Cohorts

1. Anti Alpha-Gal A Antibody Positive Cohort

2. Anti Alpha-Gal A Antibody Negative Cohort

3. Female Cohort

4. Renal Cohort

5. Cardiac Cohort

Group Type: EXPERIMENTAL

ST-920

Intervention Type: BIOLOGICAL

Single dose of investigational product ST-920

Interventions

ST-920

Single dose of investigational product ST-920

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• ≥ 18 years of age
• Documented diagnosis of Fabry disease
• One or more of the following symptoms: i) cornea verticillata, ii) acroparesthesia, iii) anhidrosis, iv) angiokeratoma
• Subject must be fully vaccinated (as per the Centers for Disease Control and Prevention (CDC) definition in the US and as per local guidelines in other countries) for COVID-19 at least one month prior to dosing

Renal Cohort:

• Screening eGFR value between 40-90 mL/min/1.73 m²
• Linear negative eGFR slope (estimated from at least 3 serum creatinine values within 18 months, including the value obtained during screening visit) of ≥ 2 mL/min/1.73m²/year

Cardiac Cohort:

• Left ventricular hypertrophy (LVH) in 2D echocardiography or CMR defined as an end diastolic septum and posterior wall thickness ≥12 mm with no other explanation for LVH, OR presentation with cardiac changes indicative of disease progression such as decreased global longitudinal strain on 2D strain echocardiography or low native T1 mapping on CMR

Exclusion Criteria

• Neutralizing antibodies to AAV6
• eGFR < 40 ml/min/1.73m2
• New York Heart Association Class III or higher
• Active infection with hepatitis A, B or C, HIV or TB
• History of liver disease such as clinically significant steatosis, fibrosis, non-alcoholic steatohepatitis (NASH) and cirrhosis, biliary disease within 6 months of informed consent; except for Gilbert's syndrome
• Elevated circulating serum AFP
• Recent or recurrent hypersensitivity response to ERT within within 6 months prior to consent
• Current or history of systemic (IV or oral) immunomodulatory agents, or biologics or steroid use in the past 6 months prior to consent (topical treatment and inhaled allowed).
• Contraindication to use of corticosteroids
• History of malignancy except for non-melanoma skin cancer and localized prostate cancer treated with curative intent
• Recent history of alcohol or substance abuse
• Participation in investigational interventional drug or medical device study throughout the duration of this study and within previous 3 months prior to consent
• Prior treatment with a gene therapy product
• Known hypersensitivity to components of ST-920 formulation
• Any other reason that, in the opinion of the Site Investigator or Medical Monitor, would render the subject unsuitable for participation in the study including but not limited to risk of COVID-19 infection

Renal cohort:

• History of renal dialysis or transplantation
• History of acute kidney insufficiency in the 6 months prior to screening
• Angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy initiated within 4 weeks prior to screening or changed ACE inhibitor or ARB dose in the 4 weeks prior to screening
• Urine protein to creatinine ratio (UPCR) > 0.5 g/g who are not being treated with an ACE inhibitor or ARB

Cardiac cohort:

• Significant cardiac fibrosis defined by late gadolinium enhancement on CMR
• Any contraindications to CMR as per local hospital/institution guidelines
• Angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy initiated within 4 weeks prior to screening or changed ACE inhibitor or ARB dose in the 4 weeks prior to screening
• NYHA Class IV

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sangamo Therapeutics

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Medical Monitor

Role: STUDY_DIRECTOR

Sangamo Therapeutics, Inc.

Locations

University of California, Irvine

Irvine, California, United States

University of South Florida

Tampa, Florida, United States

Emory University School of Medicine

Atlanta, Georgia, United States

Ann & Robert H. Lurie Children's Hospital of Chicago

Chicago, Illinois, United States

University of Iowa Hospital and Clinics

Iowa City, Iowa, United States

University of Minnesota Medical Center

Minneapolis, Minnesota, United States

Mt. Sinai School of Medicine

New York, New York, United States

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States

Lysosomal and Rare Disorders Research and Treatment Center (LDRTC)

Fairfax, Virginia, United States

The Royal Melbourne Hospital

Parkville, Victoria, Australia

M.A.G.I.C. Clinic Ltd.

Calgary, Alberta, Canada

University Medical Center Hamburg-Eppendorf

Hamburg, , Germany

University Hospital of Würzburg

Würzburg, , Germany

Azienda Ospedaliero-Universitaria Careggi

Florence, Tuscany, Italy

National Taiwan University Hospital

Taipei, , Taiwan

Queen Elizabeth Hospital

Birmingham, , United Kingdom

Addenbrooke's Hospital

Cambridge, , United Kingdom

Royal Free Hospital

London, , United Kingdom

Countries

United States; Australia; Canada; Germany; Italy; Taiwan; United Kingdom

Other Identifiers

ST-920-201

Identifier Type: -

Identifier Source: org_study_id